M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
Some big deals in the second quarter have raised hopes that takeouts are back.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Conference activity picks up, with the big one – ASCO – at the end of the month.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
AACR approaches, along with ASCO abstract titles.
The company buys Belgium’s EsoBiotec for $425m.
At long last luvelta-T is shelved, and Sutro seeks a new focus.